Hepatitis C Therapy
Migenix reports celgosivir combination therapy shows positive benefit in hepatitis C
Published in Hepatitis Weekly, December 11th, 2006
Migenix, Inc. (MGI, MGIFF) has demonstrated proof-of-concept and evidence of clinical benefit in a phase II study using the oral alpha-glucosidase inhibitor, celgosivir (MX-3253), in combination with pegylated interferon and ribavirin as compared to treatment with pegylated interferon and ribavirin alone in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated interferon plus ribavirin (considered as one of the most difficult to treat HCV patient populations).
Jim DeMesa, MD, president and CEO of Migenix, stated, "The top-line results from this study are very encouraging and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-12-11)
More Articles from Hepatitis Weekly
- Hepatitis A Virus
New hepatitis a virus research reported from Geneva University, Department of Clinical Neurosciences - Hepatitis A Virus
Studies from Institute of Medical Science update current data on hepatitis a virus - Hepatitis A Virus
Study findings from Center for Infections provide new insights into hepatitis a virus - Hepatitis B Virus
Reports from Columbia University, College of Physicians & Surgeons highlight recent research in hepatitis b virus - Hepatitis B Virus
Reports summarize hepatitis b virus research from Royal Free and University College - Hepatitis B Virus
Research from Korea University, Department of Microbiology yields new data on hepatitis b virus - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
